AstriVax is a clinical-stage biopharmaceutical company that specializes in developing innovative DNA-based vaccines using its proprietary Plug & Play vaccine platform. This patented technology utilizes self-amplifying live attenuated viral vectors to deliver antigens, which are designed to elicit robust polyfunctional immune responses. The platform is versatile, allowing for applications in both prophylactic and therapeutic settings, and aims to tackle significant health challenges, particularly in the context of viral infections such as Hepatitis B and Human Papillomavirus (HPV).

The company is advancing several vaccine candidates through its pipeline, including AVX70371 for chronic Hepatitis B, which targets specific T-cell responses to potentially achieve a functional cure. Additionally, AstriVax is developing next-generation vaccines for yellow fever (AVX70120) and rabies (AVX70481), both of which utilize a plasmid DNA approach that enhances stability and simplifies manufacturing processes. These vaccines are designed to be thermostable, addressing logistical challenges in vaccine distribution, and aim to improve treatment outcomes for diseases with significant public health implications.

Belgium

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

AstriVax

Company Details